Related Party - Gilead Sciences, Inc. - Additional Information (Details) $ / shares in Units, $ in Millions	1 Months Ended		12 Months Ended
	Oct. 31, 2022	Jan. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) Program $ / shares	Dec. 31, 2021 USD ($) Program shares	Dec. 31, 2020 USD ($) shares
Related Party Transaction [Line Items]
Issuance of common stock					$ 326
Research and Development
Related Party Transaction [Line Items]
Reimbursed under cost-sharing provisions of arrangement			$ 132	$ 25	3
General and Administrative
Related Party Transaction [Line Items]
Reimbursed under cost-sharing provisions of arrangement			1
Amended Investor Rights Agreement
Related Party Transaction [Line Items]
Lockup period	2 years
Extended lockup period	3 years
Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Option payment upon achievement of certain development milestones			150
Option payment upon completion of certain IND-enabling activities			60
Amended Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Number of exercise option to programs | Program				3
Upfront cash payment			725
Option payments received		$ 725
Option continuation payment due upon second anniversary of agreement			$ 100
Removal of option continuation payment under agreement				$ 100
Gilead
Related Party Transaction [Line Items]
Percentage of outstanding common stock held			18.90%
Gilead | Research and Development
Related Party Transaction [Line Items]
Reimbursed under cost-sharing provisions of arrangement			$ 132	$ 25	$ 3
Gilead | General and Administrative
Related Party Transaction [Line Items]
Reimbursed under cost-sharing provisions of arrangement			$ 1
Gilead | Stock Purchase Agreement
Related Party Transaction [Line Items]
Issuance of common stock, shares | shares				5,650,000	5,963,029
Issuance of common stock				$ 220
Funds received for purchase of common stock					$ 200
Purchase price of common stock allocation to performance obligation					$ 91
Percentage of premium purchase price of common stock			20.00%
Trailing days average closing price			5 days
Share Price | $ / shares			$ 33.54
Gilead | Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Collaboration term for current and future clinical programs					10 years
Upfront cash payment					$ 175
Option fee per program for all other programs entering clinical development to exercise option					150
Option continuation payment due upon second anniversary of agreement					100
Option continuation payment due upon fourth anniversary of agreement					100
Option continuation payment due upon sixth anniversary of agreement					100
Option Continuation Payment Due Upon Eighth Anniversary of Agreement					100
Number of research programs | Program			2
Revenue recognized			$ 107	$ 361	71
Gilead | Maximum | Stock Purchase Agreement
Related Party Transaction [Line Items]
Right to purchase additional outstanding voting common stock percentage			35.00%
Gilead | Maximum | Gilead Collaboration Agreement
Related Party Transaction [Line Items]
Potential regulatory approval milestones payment receivable related to domvanalimab					$ 500